A new treatment for overactive bladder has been approved for use by the NHS in Scotland, with England and Wales set to follow suit.
The Scottish Medicines Consortium has accepted mirabegron (Betmiga) for treating the symptoms of overactive bladder syndrome, including frequency and incontinence, in adults.
Mirabegron is an oral beta-3-adrenoceptor agonist, which causes the bladder to relax and therefore helps it to fill and also to store urine. It will be available as 25mg and 50mg tablets.
In guidance the SMC said the drug was associated with modest treatment benefits over placebo.
Meanwhile, the National Institute for Health and Care Excellence said in draft guidance that it also planned to recommend the drug as an option for treating overactive bladder symptoms.
However, NICE said mirabegron should only be an option for people in whom antimuscarinic drugs are contraindicated or clinically ineffective, or have unacceptable side effects. Final guidance is expected in June, subject to appeal.